Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udai Banerji

Showing results (1-10 of 129) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Heat shock protein 90 as a drug target: some like it hotUdai Banerji
Seminars in Oncology|September 25, 2016
Critical parameters in targeted drug development: the pharmacological audit trailUdai Banerji, Paul Workman
British Journal of Cancer|January 8, 2016
Antibody-drug conjugates--an emerging class of cancer treatmentNikolaos Diamantis, Udai Banerji
British Journal of Cancer|April 16, 2021
Searching for treatments for non-G12C-KRAS mutant cancersChristina Guo, Udai Banerji
Methods in Molecular Biology (Clifton, N.J.)|July 22, 2017
Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein QuantificationAdam Stewart, Udai Banerji
Nature Reviews. Clinical Oncology|December 21, 2023
Optimizing the FDA's Project Optimus: opportunities and challengesSimon Rodney, Udai Banerji
Journal of Neuro-Oncology|July 26, 2011
Revisiting the role of molecular targeted therapies in patients with brain metastasesDionysis Papadatos-Pastos, Udai Banerji
Pharmacology & Therapeutics|December 7, 2016
Maximising the potential of AKT inhibitors as anti-cancer treatmentsJessica S Brown, Udai Banerji
Nature Reviews. Clinical Oncology|July 6, 2016
Combine and conquer: challenges for targeted therapy combinations in early phase trialsJuanita S Lopez, Udai Banerji
Current Cancer Drug Targets|October 8, 2003
The clinical applications of heat shock protein inhibitors in cancer - present and futureUdai Banerji, Ian Judson, Paul Workman
Pageof 13

Showing results (1-10 of 129) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Heat shock protein 90 as a drug target: some like it hotUdai Banerji
Seminars in Oncology|September 25, 2016
Critical parameters in targeted drug development: the pharmacological audit trailUdai Banerji, Paul Workman
British Journal of Cancer|January 8, 2016
Antibody-drug conjugates--an emerging class of cancer treatmentNikolaos Diamantis, Udai Banerji
British Journal of Cancer|April 16, 2021
Searching for treatments for non-G12C-KRAS mutant cancersChristina Guo, Udai Banerji
Methods in Molecular Biology (Clifton, N.J.)|July 22, 2017
Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein QuantificationAdam Stewart, Udai Banerji
Nature Reviews. Clinical Oncology|December 21, 2023
Optimizing the FDA's Project Optimus: opportunities and challengesSimon Rodney, Udai Banerji
Journal of Neuro-Oncology|July 26, 2011
Revisiting the role of molecular targeted therapies in patients with brain metastasesDionysis Papadatos-Pastos, Udai Banerji
Pharmacology & Therapeutics|December 7, 2016
Maximising the potential of AKT inhibitors as anti-cancer treatmentsJessica S Brown, Udai Banerji
Nature Reviews. Clinical Oncology|July 6, 2016
Combine and conquer: challenges for targeted therapy combinations in early phase trialsJuanita S Lopez, Udai Banerji
Current Cancer Drug Targets|October 8, 2003
The clinical applications of heat shock protein inhibitors in cancer - present and futureUdai Banerji, Ian Judson, Paul Workman
Pageof 13